Pacylex Pharmaceuticals, Inc. With a focus on multiple common cancers, Pacylex is developing PCLX-001, a first-of-its-kind oral therapy that targets myristoylation, a previously-unknown therapeutic target in cancer treatment. By attacking the membrane-associated proteins responsible for cancer signaling, PCLX-001 offers a powerful alternative to traditional chemotherapies and immunotherapies.

In ongoing Phase 1 clinical trials, PCLX-001 has demonstrated excellent bioavailability, safety profile, and efficacy in various cancer types. One of the remarkable aspects of Pacylex's approach is their diagnostic technology. Through the identification of a sensitivity biomarker found in 19 types of cancer, they can identify patients who will benefit most from their drug, sparing many unnecessary treatments.

Pacylex is actively seeking Series B investors to support Phase 2 programs in leukemia and lymphoma, with the goal of registration filings by 2025. With a team consisting of experienced professionals in drug development and clinical operations, Pacylex is making a real difference in cancer care by providing innovative solutions and improved survival rates for patients